Gajendran Mahesh, Umapathy Chandraprakash, Perisetti Abhilash, Loganathan Priyadarshini, Dwivedi Alok, Alvarado Luis A, Zuckerman Marc J, Goyal Hemant, Elhanafi Sherif
Paul L Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, Texas, USA.
Gastroenterology, UT Health San Antonio Long School of Medicine, San Antonio, Texas, USA.
Frontline Gastroenterol. 2021 Jul 2;13(4):295-302. doi: 10.1136/flgastro-2021-101850. eCollection 2022.
Cirrhosis is the number one cause of non-cancer deaths among gastrointestinal diseases and is responsible for significant morbidity and healthcare utilisation. The objectives were to measure the 30-day readmissions rate following index hospitalisation, to determine the predictors of readmission, and to estimate the cost of 30-day readmission in patients with decompensated cirrhosis.
We performed a retrospective cohort study of patients with decompensated cirrhosis using 2014 Nationwide Readmission Database from January to November. Decompensated cirrhosis was identified based on the presence of at least one of the following: ascites, hepatic encephalopathy, variceal bleeding, spontaneous bacterial peritonitis and hepatorenal syndrome. We excluded patients less than 18 years of age, pregnant patients, patients with missing length of stay data, and those who died during the index admission.
Among 57 305 unique patients with decompensated cirrhosis, the 30-day readmission rate was 23.2%. The top three predictors of 30-day readmission were leaving against medical advice (AMA), ascites and acute kidney injury, which increased the risk of readmission by 47%, 22% and 20%, respectively. Index admission for variceal bleeding was associated with a lower 30-day readmission rate by 18%. The estimated total cost associated with 30-day readmission in our study population was US$234.4 million.
In a nationwide population study, decompensated cirrhosis is associated with a 30-day readmission rate of 23%. Leaving AMA, ascites and acute kidney injury are positively associated with readmission. Targeted interventions and quality improvement efforts should be directed toward these potential risk factors to reduce readmissions.
肝硬化是胃肠道疾病中非癌症死亡的首要原因,会导致严重的发病率和医疗资源利用。本研究的目的是测量肝硬化失代偿期患者首次住院后的30天再入院率,确定再入院的预测因素,并估算30天再入院的费用。
我们使用2014年全国再入院数据库,对1月至11月期间肝硬化失代偿期患者进行了一项回顾性队列研究。肝硬化失代偿期的诊断基于以下至少一项的存在:腹水、肝性脑病、静脉曲张出血、自发性细菌性腹膜炎和肝肾综合征。我们排除了年龄小于18岁的患者、孕妇、住院时间数据缺失的患者以及在首次入院期间死亡的患者。
在57305例肝硬化失代偿期患者中,30天再入院率为23.2%。30天再入院的前三大预测因素是违反医嘱出院(AMA)、腹水和急性肾损伤,它们使再入院风险分别增加了47%、22%和20%。静脉曲张出血的首次入院与30天再入院率降低18%相关。在我们的研究人群中,与30天再入院相关的估计总成本为2.344亿美元。
在一项全国性人群研究中,肝硬化失代偿期的30天再入院率为23%。违反医嘱出院、腹水和急性肾损伤与再入院呈正相关。应针对这些潜在风险因素进行有针对性的干预和质量改进努力,以减少再入院率。